Merck & Co.: Pipeline Resilience To Unlock Value

I initiate on (NYSE: MRK ) with a Strong Buy and $139 PT. Merck & Co., Inc. is a leading global healthcare company with market-leading positions in oncology, vaccines, and animal health. My conviction is based on resilient execution (Hi, I'm Oskar Goyvaerts, Chief Investment Officer at Moretus Investments L.P., a value-focused hedge fund. At Moretus, we specialize in identifying deeply undervalued businesses trading significantly below intrinsic value. Our disciplined, fundamentals-driven approach has consi ...